Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Exclusion Criteria

• •Women of childbearing potential if pregnant, test positive for pregnancy at Screening Visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
• •Severe central visual field loss.
• •Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (20/80 Snellen equivalent).
• •Chronic, recurrent or severe inflammatory eye disease.
• •Ocular trauma within the preceding 6 months.
• •Ocular infection or ocular inflammation within the preceding 3 months.
• •Clinically significant or progressive retinal disease.
• •Other ocular pathology.
• •Intraocular surgery within the 6 months prior to entry.
• •Ocular laser surgery within the 3 months prior to entry.
• •Any abnormality preventing reliable applanation tonometry.
• •Any other conditions, including severe illness, which would make the subject, in the opinion of the Investigator, unsuitable for the study.
• •Recent use of high-dose (\>1 gram daily) salicylate therapy.
• •Recent, current, or anticipated treatment with any medication that augments adrenergic responses, or precludes use of an alpha-adrenergic agonist.
• •Concurrent use of glucocorticoid medications administered by any route.
• •Other protocol-specified exclusion crtieria may apply.